title: Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
abstract: Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors.
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Bichakjian
authors.forename: Thomas
authors.initials: T
authors.lastname: Olencki
authors.forename: Sumaira Z
authors.initials: SZ
authors.lastname: Aasi
authors.forename: Murad
authors.initials: M
authors.lastname: Alam
authors.forename: James S
authors.initials: JS
authors.lastname: Andersen
authors.forename: Daniel
authors.initials: D
authors.lastname: Berg
authors.forename: Glen M
authors.initials: GM
authors.lastname: Bowen
authors.forename: Richard T
authors.initials: RT
authors.lastname: Cheney
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Daniels
authors.forename: L Frank
authors.initials: LF
authors.lastname: Glass
authors.forename: Roy C
authors.initials: RC
authors.lastname: Grekin
authors.forename: Kenneth
authors.initials: K
authors.lastname: Grossman
authors.forename: Susan A
authors.initials: SA
authors.lastname: Higgins
authors.forename: Alan L
authors.initials: AL
authors.lastname: Ho
authors.forename: Karl D
authors.initials: KD
authors.lastname: Lewis
authors.forename: Daniel D
authors.initials: DD
authors.lastname: Lydiatt
authors.forename: Kishwer S
authors.initials: KS
authors.lastname: Nehal
authors.forename: Paul
authors.initials: P
authors.lastname: Nghiem
authors.forename: Elise A
authors.initials: EA
authors.lastname: Olsen
authors.forename: Chrysalyne D
authors.initials: CD
authors.lastname: Schmults
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Sekulic
authors.forename: Ashok R
authors.initials: AR
authors.lastname: Shaha
authors.forename: Wade L
authors.initials: WL
authors.lastname: Thorstad
authors.forename: Malika
authors.initials: M
authors.lastname: Tuli
authors.forename: Marshall M
authors.initials: MM
authors.lastname: Urist
authors.forename: Timothy S
authors.initials: TS
authors.lastname: Wang
authors.forename: Sandra L
authors.initials: SL
authors.lastname: Wong
authors.forename: John A
authors.initials: JA
authors.lastname: Zic
authors.forename: Karin G
authors.initials: KG
authors.lastname: Hoffmann
authors.forename: Anita
authors.initials: A
authors.lastname: Engh
mesh_terms: D006801:Humans; D002280:Basal Cell Carcinoma / Q000175:diagnosis / Q000628:therapy; D012878:Skin Neoplasms / Q000175:diagnosis / Q000628:therapy; D014481:United States